Intrexon Corp – Common Stock Purchase Agreement (April 4th, 2014)
THIS COMMON STOCK PURCHASE AGREEMENT (this Agreement) is entered into as of the last date signed below (Effective Date) by and among Intrexon Corporation, a Virginia corporation (the Company), and each of those persons and entities, severally and not jointly, who have executed a signature page to this Agreement accepted and executed by the Company (which persons and entities are hereinafter collectively referred to as Subscribers and each individually as a Subscriber).
Intrexon Corp – Limited Liability Company Agreement of S & I Ophthalmic, Llc (October 30th, 2013)
THIS LIMITED LIABILITY COMPANY AGREEMENT (this Agreement) is entered into effective as of September 30, 2013 (the Effective Date), by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (Intrexon), CARACO PHARMACEUTICAL LABORATORIES LTD., a Michigan corporation with offices at 1150 Elijah McCoy Drive, Detroit, Michigan, 48202 (Caraco), and S & I Ophthalmic, LLC, a limited liability company with a registered office at Corporation Trust Center, 1209 Orange St., Wilmington, DE 19801 (the Company). (Intrexon, Caraco, and any other person who may be admitted to the Company as a member in the future in accordance with this Agreement are sometimes referred to in this Agreement, collectively, as the Members and, individually, as a Member).
Intrexon Corp – First Amendment to the Stock Purchase and Issuance Agreement (October 1st, 2013)
THIS FIRST AMENDMENT (the Amendment) to the Stock Purchase and Issuance Agreement dated September 30, 2013 (the Agreement) by and among Oragenics, Inc., a Florida corporation (the Company) and Intrexon Corporation, a Virginia corporation (Intrexon), is effective as of September 30, 2013.
Intrexon Corp – Exclusive Channel Collaboration Agreement (May 31st, 2013)
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the Agreement) is made and entered into effective as of March 29, 2013 (the Effective Date) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (Intrexon), and GENOPAVER, LLC, a Delaware limited liability company having a place of business at 2875 South Ocean Boulevard, Suite 214, Palm Beach, FL 33480 (Genopaver). Intrexon and Genopaver may be referred to herein individually as a Party, and collectively as the Parties.
New River Pharmaceuticals – Manufacturing Services Agreement Between Patheon Pharmaceuticals Inc. And New River Pharmaceuticals Inc. August 18, 2006 (November 9th, 2006)
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
New River Pharmaceuticals – A - 16 (July 27th, 2006)
New River Pharmaceuticals – NRP104 ACTIVE PHARMACEUTICAL INGREDIENT SUPPLY AGREEMENT by and Between Supplier Name: (July 13th, 2006)
THIS SUPPLY AGREEMENT (the "Agreement") is entered into as of May 18, 2006 (the "Effective Date"), by and between ORGANICHEM CORPORATION, a Delaware corporation, with offices at 33 Riverside Avenue, Rensselaer, New York 12144 ("ORGANICHEM") and NEW RIVER PHARMACEUTICALS INC., a Virginia corporation, with corporate offices at 1881 Grove Avenue, Radford, Virginia 24141 and its designees ("NEW RIVER").
New River Pharmaceuticals – Modification of Lease (April 1st, 2005)
THIS MODIFICATION OF LEASE is made and entered into as of the 1st day of August, 2004, by and between Virginia Tech Foundation, Inc., hereinafter called the Landlord, and New River Pharmaceuticals Inc., hereinafter called Tenant. The terms Landlord and Tenant are intended to include the successors and assigns of the original parties and their heirs, legal representatives, successors and assigns of the respective entities.
New River Pharmaceuticals – Wells Fargo Securities LLC Healthcare Conference 2005 (March 1st, 2005)
This presentation may contain forward-looking statements that reflect managements current views as to the Companys clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statements involve uncertainties and risks that are detailed in the Companys final prospectus filed with the SEC on August 5, 2004, under Rule 424(b) of the Securities Act of 1933 as well as other public filings with the SEC. Actual results could differ materially from these forward-looking statements.